



Financial Tear Sheet

Corporate Profile

Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket's multi-platform development approach applies the well-established lentiviral virus, which we refer to as LVV, adeno-associated virus, which we refer to as AAV, gene therapy platforms.

Primary IR Contact

The Alexandria Center for
Life Science

Phone:

646-440-9100

E-mail:

info@rocketpharma.com

Stock Performance

RCKT (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$19.89
Change (%)	▲ 0.50 (2.58%)

Volume	158,362
52 Week High	\$24.28
52 Week Low	\$3.74
Market Cap	\$769,024,735
Rolling EPS	-2.63
PE Ratio	0
Shares Outstanding	39,660,894
Data as of August 16, 2018 4:00 p.m. ET	

Recent News & Events

August 08, 2018

[Rocket Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights](#)

June 22, 2018

[Rocket Pharmaceuticals to Join Russell 3000® and 2000® Indexes](#)

May 30, 2018

[Rocket Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
08/14/18	10-Q
08/03/18	4
07/05/18	EFFECT
06/28/18	4

Corporate Governance

David P. Southwell	President and Chief Executive Officer
Rudolf A. Baumgartner, MD	Executive Vice President, Chief Medical Officer
Dale Ritter	Vice President, Finance & Chief Accounting Officer
Claudine Prowse, PhD	Vice President, Strategy, Corporate Development & IRO

Data provided by Nasdaq. Minimum 15 minutes delayed.